High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia

[1]  L. Escoda,et al.  Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. , 2003, Blood.

[2]  D. Liang,et al.  Internal tandem duplication and Asp835 mutations of the FMS‐like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia , 2003, Cancer.

[3]  L. Chan,et al.  Trisomy 21 and other chromosomal abnormalities in acute promyelocytic leukemia. , 2003, Cancer genetics and cytogenetics.

[4]  Axel Benner,et al.  Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.

[5]  F. Mandelli,et al.  Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol , 2002, Leukemia.

[6]  T. Ley,et al.  PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Margaret T May,et al.  Regression Modelling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. Frank E Harrell Jr, New York: Springer 2001, pp. 568, $79.95. ISBN 0-387-95232-2. , 2002 .

[8]  S. Fröhling,et al.  Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Degos,et al.  All trans retinoic acid in acute promyelocytic leukemia , 2001, Oncogene.

[10]  C. Niu,et al.  Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia , 2001, Leukemia.

[11]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[12]  H. Dombret,et al.  Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial , 2000, British journal of haematology.

[13]  H. Dombret,et al.  Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia , 2000, Leukemia.

[14]  W. Hiddemann,et al.  Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia , 2000, Leukemia.

[15]  J. Miguel,et al.  A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. , 1999, Blood.

[16]  T. Naoe,et al.  Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia , 1997, Leukemia.

[17]  T. Barbui,et al.  Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy , 1997 .

[18]  P. Thall,et al.  Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Mehta,et al.  Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia , 1997, British journal of haematology.

[20]  S. Fröhling,et al.  Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia. , 1996, Blood.

[21]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[22]  F. Mandelli,et al.  AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. , 1996, Blood.

[23]  R. Braziel,et al.  Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. , 1995, Blood.

[24]  E. Thiel,et al.  Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo , 1993, Annals of Hematology.

[25]  Zi X. Chen,et al.  A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. , 1991, Blood.

[26]  C. Bloomfield,et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[28]  E. Korn.  Censoring distributions as a measure of follow-up in survival analysis. , 1986, Statistics in medicine.

[29]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[30]  M. Halperin.  Estimation in the Truncated Normal Distribution , 1952 .

[31]  T. Ley,et al.  PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Esteve,et al.  Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. , 2001, Haematologica.

[33]  J. Esteve,et al.  From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use , 2000 .

[34]  H. Dombret,et al.  Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. , 2000, Leukemia.

[35]  J. Esteve,et al.  A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. , 1999, Blood.

[36]  T. Barbui,et al.  Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. , 1997, Blood.

[37]  F. Mitelman.  ISCN 1995 : an international system for human cytogenetic nomenclature (1995) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature : Memphis, Tennessee, USA, October 9-13, 1994 , 1995 .

[38]  E. Thiel,et al.  Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group. , 1993, Annals of hematology.

[39]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[40]  C. Bloomfield,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol , 2022 .

[41]  D. Grimwade,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All- Trans Retinoic Acid: Result of the Randomized MRC Trial , 2022 .

[42]  D.,et al.  Regression Models and Life-Tables , 2022 .